• In late July 2025, Exact Sciences Corp. announced an expanded partnership with Humana, making its next-generation Cologuard Plus™ colorectal cancer screening test available as an in-network benefit for approximately 5.8 million Humana Medicare Advantage members nationwide starting August 2025.
• This collaboration broadens access to noninvasive cancer screening, highlighting the continued momentum and clinical validation for Exact Sciences’ flagship products among major payers and patient populations.
• We'll examine how nationwide access to Cologuard Plus for Humana Medicare members shapes Exact Sciences’ long-term growth outlook.

AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Exact Sciences Investment Narrative Recap

To be a shareholder of Exact Sciences, you need to believe in the advance of noninvasive cancer screening and the company's ability to drive broad payer access for its molecular diagnostic portfolio. The expanded Humana partnership provides Cologuard Plus with exposure to a sizeable Medicare Advantage population, solidifying its status as a major near-term growth catalyst; however, risks such as delayed Medicare pricing revisions and phased adoption timelines remain pertinent for short-term revenues, and the news does not eliminate these uncertainties.

Among recent developments, the launch and rapid payer adoption of Cologuard Plus stand out as a crucial driver for screening revenue, supporting Exact Sciences’ expansion efforts with major national insurers like Humana. This alignment strengthens one of the company's main growth levers in 2025, coinciding with ongoing efforts to bring new tests like Oncodetect to market.

In contrast, investors should be aware of the continued risk from Medicare pricing revision delays, which could ...

Exact Sciences' narrative projects $4.0 billion revenue and $232.6 million earnings by 2028. This requires 12.2% yearly revenue growth and a $1.23 billion earnings increase from current earnings of -$1.0 billion.

Uncover how Exact Sciences' forecasts yield a $68.54 fair value, a 44% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community span a wide range, from US$68.54 to US$133.96. With Cologuard Plus identified as a significant catalyst, opinion diversity underscores the importance of reviewing multiple views on Exact Sciences’ future.

Explore 5 other fair value estimates on Exact Sciences - why the stock might be worth just $68.54!

Build Your Own Exact Sciences Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Exact Sciences research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Exact Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Exact Sciences' overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• We've found 22 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.